Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression

N/ACompletedNCT02742064

Cogito Health Inc899 enrolled

Overview

The purpose of this study is to determine if a mobile sensing platform can passively and objectively detect the presence of clinically significant mood disorder symptomatology and symptom progression over time. Meeting this goal will allow for improved risk categorization, prediction of relapse, and measurement of disease progression in a lifetime prevalence population.

Study Type

OBSERVATIONAL

Enrollment

899

Conditions

Depression Bipolar Disorder

Interventions

Cogito Companion Mobile Phone ApplicationOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 or older * Have a smartphone and cell service plan, including voice and data, that meets the device requirements of the Mobile Sensing Platform. * Enrolled in the MoodNetwork Exclusion Criteria: * Report positively on the QIDS-SR suicide item during study intake * Total score greater than 15 on the QIDS-SR during the screening process

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Severity of MDD symptoms as assessed by QIDS SR

Time frame: 6 months

Severity of Mania symptoms as assessed by ASRM

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.